Hansa Biopharma's CEO Søren Tulstrup provides an update and an interesting insight into Hansa's European launch of Imlifidase. The product was recently approved, giving hope and future life for these highly sensitized patients stuck in a queue waiting for a new kidney. This journey towards a future life includes gradual progress, extending the number of reference specialist centers using Imlifidase, expanding the number of countries reimbursing Imlifidase and eventually a much-improved standard of care for these patients in Europe and beyond.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se